Literature DB >> 7507496

Human myelin basic protein (MBP) epitopes recognized by mouse MBP-selected T cell lines from multiple sclerosis patients.

Y K Chou1, R E Jones, D Bourdette, R Whitham, G Hashim, J Atherton, H Offner, A A Vandenbark.   

Abstract

We investigated whether myelin basic protein (MBP)-reactive T cells from multiple sclerosis (MS) patients can recognize mouse MBP since this is an expected requirement for the transfer of experimental autoimmune encephalomyelitis (EAE) into severe combined immunodeficiency (SCID) mouse-human chimeras. Peripheral blood mononuclear cells from 11 MS patients were analyzed for in vitro proliferation to mouse MBP. Six patients (55%) responded to mouse MBP at the first or second stimulation. Five T cell lines, selected with mouse MBP from five MS patients, were analyzed for their proliferation to mouse and human MBP and to a panel of synthetic peptides of human MBP. Four of the five lines recognized mouse MBP. In vitro proliferation was restricted by MHC class II in one line tested for MHC restriction. One of the five lines recognized whole human MBP and all five of the lines responded to at least one of the five synthetic peptides corresponding to human MBP residues 8-28, 67-90, 84-102, 87-99 or 130-149. These results show that MS patient T cells recognize mouse MBP and suggest that distinct human MBP epitopes are immunologically cross-reactive with epitopes of mouse MBP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507496     DOI: 10.1016/0165-5728(94)90179-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  Unmasking of an unusual myelin basic protein epitope during the process of myelin degeneration in humans: a potential mechanism for the generation of autoantigens.

Authors:  A Matsuo; G C Lee; K Terai; K Takami; W F Hickey; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

2.  Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.

Authors:  E A Elliott; H I McFarland; S H Nye; R Cofiell; T M Wilson; J A Wilkins; S P Squinto; L A Matis; J P Mueller
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.